Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.
about
Physicians' preference values for hepatitis C health states and antiviral therapy: a surveyEffects of a self-care program on quality of life of cirrhotic patients referring to Tehran Hepatitis CenterCancer history and other personal factors affect quality of life in patients with hepatitis C.Extrahepatic manifestations of chronic hepatitis C virus infectionHepatitis C virus infection in san francisco’s HIV-infected urban poorMode of transmission, rather than the hepatitis C virus, as a major determinant of poor interpersonal relationships in patients with chronic hepatitis CSocio-demographic and clinical features of Irish iatrogenic hepatitis C patients: a cross-sectional surveyChronic hepatitis C virus infection and neurological and psychiatric disorders: an overviewNatural history of chronic hepatitis CCost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.Cerebral dysfunction in chronic hepatitis C infection.Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection.Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment.Quality of life measurement in gastrointestinal and liver disorders.Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases.Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyQuality of life measurement in gastroenterology: what is available?The increasing problem of hepatitis C virus infection.Hepatitis C virus infection as a traumatic experienceIs severe liver disease a common outcome for people with chronic hepatitis C?Hepatitis C advances in antiviral therapy: what is accepted treatment now?Health-related quality of life and gastrointestinal disease.Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.The burden of hepatitis C in the United States.Introduction to therapy of hepatitis C.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada).Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of lifeCost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.The Association of Chronic Hepatitis C with Respiratory Microbiota Disturbance on the Basis of Decreased Haemophilus Spp. ColonizationTherapeutic modalities in hepatitis C: challenges and development.Health-related quality of life in patients with chronic hepatitis C and advanced fibrosisChronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural EgyptEstimation of utilities for chronic hepatitis C from SF-36 scores.Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.Effect of healthcare insurance policy on the quality of life of chronic hepatitis C patients receiving interferon α-2a plus ribavirin therapy.Hepatitis C virus infection, and neurological and psychiatric disorders - A review.
P2860
Q24802683-69D71BDF-FFC5-4DE1-9A17-7F94F2E44D30Q24811340-D0F09CC9-C06C-400B-84AD-230F1D05B7C2Q24814090-676DFCA1-197E-4791-99B2-4CDED9E40AEDQ26767084-074E725B-4258-459E-AE22-5178624F065BQ27473306-475445E7-F477-4951-AF9A-A363F31D20CAQ27488234-0C17FBDE-C432-498A-A37F-22537FD2423BQ27490161-EF6BFE47-5D19-416C-AD97-F2E1333BA0F7Q28082212-1D328C6D-38C6-4F64-A91C-C3783C248C95Q29620673-FBB6F87E-AD83-496C-9BB0-291937323AB2Q30444892-9B6B3D06-B40F-480B-92DF-FBC554F17C98Q30773516-60A318F4-9408-4977-8020-C433DCFF9142Q31024615-FDCAF470-B2A8-48AA-BDD0-E8A1A38FF106Q31041310-1005CD07-3D54-48AD-AC71-0E75B9F577B2Q33430951-F19AAACA-6A43-4715-9C01-4E200AA3F29BQ33953930-E6174032-5FD0-46B6-A10F-AB7F98FB09BFQ34001406-292A514D-25A5-487B-ACF3-584FBD2890D7Q34012572-FB2BD90F-0DC6-48A8-8931-AFC29BECAA68Q34072683-CE407155-0B4E-4E99-A770-CE661F4CC8B2Q34146792-7CFDFFDC-0F87-441A-BA79-CC8628BDC846Q34171464-5E000D34-B753-4CFF-83F3-BB54935E0079Q34252391-5FC01BB4-6053-4EA8-A6E1-F0874180EF67Q34395228-417CF9D0-F630-42DC-81C9-0C455BFB17A1Q34619377-C1B8B335-DB07-4ABB-A0CE-B04B1E593A18Q34619384-3CA31DA0-9800-457C-85D1-35E80EE15086Q34631350-2D4CA276-1455-4A4D-9639-F89FBC59D8F2Q34681541-79E1A524-6091-4F7A-86D5-EC36717F4FA2Q34984035-C25219AB-79AF-4D4D-A037-689C8D4160EFQ34984075-316042FD-482F-4C4B-AE57-640690F23F30Q35205389-C4B41A03-B057-4522-B713-0BF7D323D970Q35453012-78EE914E-7285-408C-B5E1-CF4E4BE3EE3AQ35596306-6983E29F-CFDA-4AEF-850C-8AA0931A5CFDQ35768976-E9B89004-AA93-45B6-9624-AA4EF591A807Q35934985-57556589-BC0A-4D88-8B90-8446763D6B86Q36011951-959DFC0E-41FD-4037-B681-F16203602FB6Q36015711-55C569C2-5234-49E3-97F1-B10DD13CDFDBQ36020207-1EE77CBF-E406-4E04-B95C-1CDEE8B5D55AQ36060018-168ABCBA-9114-4DB0-826F-65E2AF71B12BQ36203547-3D25BD5D-637E-4675-B2FF-61DEB870A081Q36224751-A4D119AD-A5C9-4669-AC7E-6D577468B371Q36266948-14731B23-032F-49C8-ACD9-C8AE7015CAAF
P2860
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Reduction of health-related qu ...... sensus Interferon Study Group.
@en
Reduction of health-related qu ...... sensus Interferon Study Group.
@nl
type
label
Reduction of health-related qu ...... sensus Interferon Study Group.
@en
Reduction of health-related qu ...... sensus Interferon Study Group.
@nl
prefLabel
Reduction of health-related qu ...... sensus Interferon Study Group.
@en
Reduction of health-related qu ...... sensus Interferon Study Group.
@nl
P356
P1433
P1476
Reduction of health-related qu ...... sensus Interferon Study Group.
@en
P2093
H L Bonkovsky
J M Woolley
P304
P356
10.1002/HEP.510290124
P407
P577
1999-01-01T00:00:00Z